Identification of molecular markers in patients with hypertensive heart disease accompanied with coronary artery disease

Genetics and Molecular Research

Volumn 14, Issue 1, 2015, Pages 93-100

  Pang, H ^a   Han, B ^a   Li, Z Y ^a   Fu, Q ^a  

^a XUZHOU CENTRAL HOSPITAL   (China)

Author keywords

Apelin; Coronary artery disease; High sensitivity C reactive protein; Hypertensive heart disease; Ox LDL

Indexed keywords

APELIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; HYPERSENSITIVE C REACTIVE PROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHEMOLUMINESCENCE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART ATRIUM ENLARGEMENT; HEART PROTECTION; HUMAN; HYPERTENSION; INFLAMMATION; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SYSTOLIC BLOOD PRESSURE; COMPLICATION; METABOLISM; MIDDLE AGED; STATISTICAL MODEL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; CORONARY ARTERY DISEASE; FEMALE; HUMANS; HYPERTENSION; LOGISTIC MODELS; MALE; MIDDLE AGED;

EID: 84921293079     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2015.January.15.12     Document Type: Article

References (17)

1. Bzowska M, Nogiec A, Skrzeczynska-Moncznik J, Mickowska B, et al. (2012). Oxidized LDLs inhibit TLR-induced IL-10 production by monocytes: a new aspect of pathogen-accelerated atherosclerosis. Inflammation 35: 1567-1584.
2. Foussal C, Lairez O, Calise D, Pathak A, et al. (2010). Activation of catalase by apelin prevents oxidative stress-linked cardiac hypertrophy. FEBS Lett. 584: 2363-2370.
3. Glasser SP, Judd S, Basile J, Lackland D, et al. (2011). Prehypertension, racial prevalence and its association with risk factors: Analysis of the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. Am. J. Hypertens. 24: 194-199.
4. Gupta P, Nagaraju SP, Gupta A and Mandya Chikkalingaiah KB (2012). Prehypertension - time to act. Saudi J. Kidney Dis. Transpl. 23: 223-233.
5. Hamer M, Chida Y and Stamatakis E (2010). Association of very highly elevated C-reactive protein concentration with cardiovascular events and all-cause mortality. Clin. Chem. 56: 132-135.
6. Iturrioz X, Alvear-Perez R, De Mota N, Franchet C, et al. (2010). Identification and pharmacological properties of E339- 3D6, the first nonpeptidic apelin receptor agonist. Faseb J. 24: 1506-1517.
7. Krumholz HM, Anderson JL, Bachelder BL, Fesmire FM, et al. (2008). ACC/AHA 2008 performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/ American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for ST-Elevation and Non-ST-Elevation Myocardial Infarction) Developed in Collaboration With the American Academy of Family Physicians and American College of Emergency Physicians Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation, Society for Cardiovascular Angiography and Interventions, and Society of Hospital Medicine. J. Am. Coll. Cardiol. 52: 2046-2099.
8. Maguire JJ, Kleinz MJ, Pitkin SL and Davenport AP (2009). [Pyr1]apelin-13 identified as the predominant apelin isoform in the human heart: vasoactive mechanisms and inotropic action in disease. Hypertension 54: 598-604.
9. Manios E, Tsivgoulis G, Koroboki E, Stamatelopoulos K, et al. (2009). Impact of prehypertension on common carotid artery intima-media thickness and left ventricular mass. Stroke 40: 1515-1518.
10. Przewlocka-Kosmala M, Kotwica T, Mysiak A and Kosmala W (2011). Reduced circulating apelin in essential hypertension and its association with cardiac dysfunction. J. Hypertens. 29: 971-979.
11. Rastaldo R, Cappello S, Folino A and Losano G (2011). Effect of apelin-apelin receptor system in postischaemic myocardial protection: a pharmacological postconditioning tool? Antiox. Redox Signal. 14: 909-922.
12. Roberts EM, Newson MJ, Pope GR, Landgraf R, et al. (2009). Abnormal fluid homeostasis in apelin receptor knockout mice. J. Endocrinol. 202: 453-462.
13. Ryden L, Standl E, Bartnik M, Van den Berghe G, et al. (2007). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur. Heart J. 28: 88-136.
14. Shan PF, Lu Y, Cui RR, Jiang Y, et al. (2011). Apelin attenuates the osteoblastic differentiation of vascular smooth muscle cells. PloS One 6: e17938.
15. Tsai WC (2011). Treatment options for hypertension in high-risk patients. Vasc. Health Risk Manage. 7: 137-141.
16. Writing Group of 2010 Chinese Guidelines for the Management of Hypertension (2011). 2010 Chinese guidelines for the management of hypertension. Chin. J. Cardiol. 39: 579-616.
17. Zhang Z, Yu B and Tao GZ (2009). Apelin protects against cardiomyocyte apoptosis induced by glucose deprivation. Chin. Med. J. 122: 2360-2365.